新型抗炎药游离甾体化合物伐莫洛酮的研究进展  

Research progress on the novel anti-inflammatory free steroid compound vamorolone(VBP15)

作　　者：张中宝[1] 王琴 何建丽 ZHANG Zhongbao;WANG Qin;HE Jiani(Department of Otolaryngology,Xiaolan People’s Hospital of Zhongshan,Zhongshan 528415,China;Department of Neurology,Xiaolan People’s Hospital of Zhongshan,Zhongshan 528415,China)

机构地区：[1]中山市小榄人民医院耳鼻喉头颈外科,广东中山528415 [2]中山市小榄人民医院神经内科,广东中山528415

出　　处：《广东药科大学学报》2024年第1期143-150,共8页Journal of Guangdong Pharmaceutical University

基　　金：中山市医学科研项目(2021A020318)。

摘　　要：伐莫洛酮是一种新型抗炎药,结构与糖皮质激素相似,相关动物及临床实验发现其在很多动物疾病模型中具有与泼尼松类似的抗炎作用,但副作用明显减少。临床研究发现其对Duchenne型肌营养不良症(duchenne muscular dystrophy,DMD)有同糖皮质激素一样的疗效,但安全性明显提高及不良事件明显减少,且伐莫洛酮治疗不会导致皮质类固醇引起的生长迟缓。本文就伐莫洛酮的药物结构及药理作用、临床试验及不良反应等研究进展进行综述,以期为其临床应用提供更多参考。Vamorolone is a novel anti-inflammatory drug with a structure similar to glucocorticoids.Related animal and clinical experiments on vamolodone have found that vamolodone has anti-inflammatory effects similar to prednisone in many animal disease models,but with significantly reduced side effects.Clinical studies have found that vamolodone has the same efficacy as glucocorticoids in Duchenne muscular dystrophy(DMD),but with a significantly improved safety profile and fewer adverse events,and vamolodone treatment does not cause corticosteroid-induced growth retardation.This article summarizes the progress of research on the structure and pharmacological effects of vamolodone,clinical trials and adverse effects,in order to provide more references for its clinical application.

关 键 词：伐莫洛酮 VBP15 新型抗炎药 游离甾体化合物 Duchenne型肌肉营养不良症 

分 类 号：R979.9[医药卫生—药品]